Completed PHASE1 INTERVENTIONAL 3-arm NCT03459391

Study to Assess Safety, Tolerability and Pharmacokinetics of XC221 in Healthy Volunteers

A Double-blind, Randomized, Placebo-controlled Study of the Safety,Tolerability and Pharmacokinetics of Increasing Doses of XC221 After Single and Repeated Oral Administration in Healthy Volunteers

Sponsor: PHARMENTERPRISES LLC

Conditions Acute Respiratory Infection Influenza

Interventions Placebo XC221 200 mg XC221 60 mg

Updated 6 times since 2018 Last updated: Mar 2, 2018 Started: May 22, 2017 Primary completion: Sep 26, 2017 Completion: Sep 26, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Acute Respiratory Infection and Influenza, this trial is completed. The trial is conducted by PHARMENTERPRISES LLC and has accumulated 6 data snapshots since 2017. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Mar 2018 — Jun 2018 [monthly]

Completed PHASE1

First recorded

May 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

PHARMENTERPRISES LLC

Data source: PHARMENTERPRISES LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Moscow, Russia